Ali Roghanian
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.
Journal: Journal of experimental & clinical cancer research : CR
Published: March 30, 2026
Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.
Journal: Immunity
Published: July 02, 2025
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.
Journal: Immunotherapy advances
Published: April 25, 2025
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.
Journal: Clinical and experimental immunology
Published: December 03, 2024
Therapeutic targeting of tumour-associated macrophage receptors.
Journal: Immunotherapy advances
Published: October 17, 2024
Human leukocyte immunoglobulin-like receptors in health and disease.
Journal: Frontiers in immunology
Published: August 25, 2023
Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.
Journal: Frontiers in immunology
Published: February 28, 2023
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Journal: Cell reports
Published: February 20, 2022
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Journal: Journal of experimental & clinical cancer research : CR
Published: October 04, 2021
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Journal: JCI insight
Published: June 22, 2020
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.
Journal: Cancer immunology research
Published: November 27, 2018
Last Updated: 09/26/2026